LexisNexis' highly useful All England Direct subscription service brings news of Mayne Pharma Pty Ltd and another v Pharmacia Italia SpA, a decision of Roger Wyand QC sitting today as a Deputy Judge in the Patents Court.
Mayne, an Australian healthcare company, wanted to import and sell epirubicin hydrochloride (an anti-tumour drug against cancer) in the form of an injectable solution, in the UK. Since Pharmacia Italia (PI) owned five UK patents for epirubicin solutions. Mayne sought a declaration of non-infringement; PI conceded non-infringement of four of them but counter-claimed for infringement of the fifth . Mayne got its declaration of non-infringement after the court construed the scope of PI's patent. At the time of writing this note, the text of this decision has not been put on BAILII or any other publicly accessible website. The IPKat wonders how this, the first case to determine a patent infringement issue after last month's House of Lords decision in Kirin-Amgen, addressed the infringement issue in the light of Lord Hoffmann's speech in that case.
ANTI-TUMOUR DRUG IMPORTS DON'T INFRINGE
![ANTI-TUMOUR DRUG IMPORTS DON'T INFRINGE]()
Reviewed by Jeremy
on
Monday, November 01, 2004
Rating:
Follow the IPKat on LinkedIn 
![[Guest post] EUIPO Second Board of Appeal refers case to Grand Board of Appeal following earlier refusal to register a photograph of a man’s head/face as an EU trade mark](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiUj9v-k3DYaSVMR4lsmKDLHVB5nIoINuvZNbH2TQCelrfaAE9qmGSAQs-plzQ7HnZ7Svk_gRdrIODp0Nat5vpWajduit3xkArNhK76AHhX770RIJ62thfCVI5fnvcXU-5zH4NkUSfPY9FjRMFiK7OKJ7m7YSo2FzhyPSoA8ZWCsxaOXb0bBCoPQA/s72-c/Picture%201.png)
![[Guest post] Benelux Office rules on opposition proceedings prepared by ChatGPT](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi29VY0rNNP1Hqyz8RgB47r4q7fhqQfYHxsEbX_RKmT4KU5Y_vg7vB6dsAW91CidjMfJ38klTvD4mMtZb3QmwFPAHaGF88BPttWSbfYvo7UUg7MpFRTNtEjThmG0QaX2qZFFHSnN71i3YQZSBFC0SL7PgkAlme-XH8cSNWRFbOAOuLr_LMOGcImLQ/s72-c/Screenshot%202024-12-04%20at%2020.45.58.png)
Posts
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html